# State of Alaska Epidemiology



# Bulletin

Department of Health and Social Services

William J. Streur, Commissioner Ward B. Hurlburt, MD, MPH, CMO

3601 C Street, Suite 540 Anchorage, Alaska 99503

http://www.epi.Alaska.gov

**Division of Public Health** 

Kerre Shelton, Director

Local (907) 269-8000 24 Hour Emergency (800) 478-0084 Editors:

Joe McLaughlin, MD, MPH Louisa Castrodale, DVM, MPH

Bulletin No. 17 August 28, 2014

# Influenza Vaccines Available during the 2014–15 Season

#### **Background**

Thirteen influenza vaccine products from seven different vaccine manufacturers will be available on the U.S. market this fall. Influenza vaccine contraindications and precautions are summarized below (Table).

#### Influenza Vaccine Composition

The 2014–15 vaccine composition is the same as for 2013–14.

- Trivalent vaccines will contain an A/California/7/2009 (H1N1)-like virus, an A/Texas/50/2012 (H3N2)-like virus, and a B/Massachusetts/2/2012-like (Yamagata lineage) virus.
- Quadrivalent vaccines will include an additional vaccine virus, a B/Brisbane/60/2008-like (Victoria lineage) virus. <sup>1</sup>

#### Influenza Vaccine Abbreviations

- IIV: inactivated influenza vaccine
- LAIV: live-attenuated influenza vaccine
- RIV: recombinant hemagglutinin (HA) influenza vaccine
- cc: a prefix indicating cell culture-based vaccine (e.g., ccIIV)
- Numeric suffix: specifies the number of antigens in the vaccine (e.g., IIV3=trivalent, and IIV4=quadrivalent)

#### **Inactivated Influenza Vaccines**

- Inactivated influenza vaccines contain inactivated viruses and thus *cannot cause influenza*.
- Vaccine composition varies according to the manufacturer (refer to package inserts).
- Single-dose preparations are thimerosal-free.
- Multidose vials contain the preservative thimerosal.
- Store at  $35^{\circ}$ – $46^{\circ}$ F ( $2^{\circ}$ – $8^{\circ}$ C); do not freeze.<sup>2</sup>
- Commonly reported adverse events: local redness and soreness at the injection-site.
- Less commonly reported adverse events: mild fever, muscle pain, and rash.
- <u>IIV4 vaccines available this season</u>: Fluarix® Quadrivalent, FluLaval® Quadrivalent, Fluzone® Quadrivalent.<sup>1</sup>
- <u>IIV3 vaccines available in the U.S. this season</u>: Afluria®, Fluarix®, FluLaval®, Fluvirin®, Fluzone®, Fluzone® Intradermal, Fluzone® High-Dose.<sup>1</sup>
- <u>ccIIV3 vaccine available this season</u>: Flucelvax®, approved for persons aged ≥18 years.<sup>2</sup> Vaccine virus strains are grown in mammalian cells; however, initial reference strains are passed through an egg and thus the vaccine should be administered following CDC's egg-allergy guidelines.<sup>1</sup>

# Live-Attenuated Influenza Vaccine

 When immediately available, LAIV4 should be used for healthy children aged 2 through 8 years who have no contraindications or precautions.

- Contains live, attenuated (weakened), temperature-sensitive (cold-adapted) viruses that are able to replicate efficiently only at temperatures present in the nasal mucosa.
- FluMist® Quadrivalent is the only LAIV available this season; it is thimerosal-free and available for healthy, non-pregnant persons aged 2–49 years.<sup>1</sup>
- FluMist® Quadrivalent is for intranasal administration only, and is supplied in a prefilled, single-use sprayer containing 0.2 mL of vaccine; an attached dose-divider clip is removed from the sprayer to administer the second half of the dose into the other nostril. Illustrations and a video showing correct administration technique are available on the manufacturer's website.<sup>3</sup>
- Store at  $35-46^{\circ}$ F ( $2^{\circ}-8^{\circ}$ C); do not freeze.<sup>2</sup>
- The most commonly reported adverse events following LAIV are nasal congestion, cough, headache, and sore throat.

#### Recombinant Influenza Vaccine

- RIV3 is made by using DNA and cell culture technology to produce the HA protein that induces immunity; the recombinant HA is produced in an insect line using a baculovirus, thus the vaccine is egg-free.<sup>2</sup>
- FluBlok® is the only RIV3 available this season; it may be used in persons aged 18–49 years.<sup>2</sup>
- Store at 35–46°F (2°–8°C), do not freeze, and protect from light.<sup>2</sup>

## **State-Supplied Influenza Vaccines**

The Alaska Immunization Program will supply the following three formulations of influenza vaccine this season:<sup>4</sup>

- Fluzone® Pediatric IIV4: prefilled syringe, preservative free, latex free, available for children aged 6–35 months.
- Fluzone® IIV4: multidose, contains thimerosal, available for persons aged ≥6 months.<sup>2</sup>
- FluMist® LAIV4: prefilled sprayer, preservative free, latex free, available for persons aged 2–49 years.<sup>3</sup>

### References

- CDC. Summary Recommendations: Prevention and Control of Influenza with Vaccines: Recommendations of the ACIP – United States, 2014–15 Influenza Season. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6332a3.htm
- U.S. Food and Drug Administration, Vaccines, Blood, and Biologics: Manufacturer Package Inserts. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833
- MedImmune Vaccines, Inc. Information for Healthcare Professionals: Dosing and Administration. Available at: https://www.flumistquadrivalent.com/hcp/
- Alaska Section of Epidemiology. Influenza Vaccine Recommendations and Administration for the 2014-15 Season. *Bulletin* No. 16. Available at: http://www.epi.alaska.gov/bulletins/docs/b2014\_16.pdf

Table. Contraindications and Precautions for Influenza Vaccines, 2014–15 Season<sup>1</sup>

Contraindications for LAIV4 and IIV	Do not administer if person has:	<ul> <li>anaphylaxis or life-threatening reaction to a previous influenza vaccine or vaccine component</li> <li>severe allergy (e.g., anaphylaxis) to egg (if RIV3 is not available, IIV should be administered by a physician experienced in recognition and management of severe allergic conditions.)</li> </ul>
Additional contraindications and precautions for LAIV4	Do not administer if person:	<ul> <li>is aged &lt;2 years or &gt;49 years</li> <li>is pregnant</li> <li>is immunosuppressed</li> </ul>
(Note: persons with contraindications for LAIV4 may be candidates for IIV or RIV.)		<ul> <li>is a child aged 2–4 years with asthma or a history of wheezing in past 12 months</li> <li>is a child aged 2–17 years receiving long-term aspirin or other salicylates therapy</li> <li>who received live virus (LAIV4, MMR, varicella) vaccine within the last 4 weeks</li> <li>who received influenza antiviral medication within the last 48 hours</li> <li>is a close contact of a patient with severe immunosuppression requiring protective isolation</li> <li>Precaution: has chronic medical conditions* (these are no longer contraindications)</li> </ul>
Contraindications for RIV	Do not administer if person:	<ul> <li>is aged &lt;18 years or ≥50 years (may be used in persons with severe allergy to egg protein.)</li> <li>has a history of severe allergic reaction to any component of the vaccine</li> </ul>
Precautions for ALL influenza vaccines	Do not administer if person:	<ul> <li>has a moderate or severe illness with or without fever (mild illness is not a precaution)</li> <li>developed Guillain Barré syndrome within 6 weeks of a previous influenza vaccination</li> </ul>

\*Chronic pulmonary (including asthma in persons ≥5 years), cardiovascular (excluding hypertension), renal, hepatic, cognitive, neurologic/neuromuscular (e.g., cerebral palsy), hematologic or metabolic disorders (e.g., diabetes).